Mednet Logo
HomePediatric Hematology/Oncology
Pediatric Hematology/Oncology

Pediatric Hematology/Oncology

Clinical discussions on pediatric blood disorders, childhood cancers, and specialized treatment protocols.

Recent Discussions

How would you manage a patient with radiation pneumonitis who remains symptomatic on steroids?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Tennessee Oncology

Engage your Pulmonology colleagues to assist in these difficult cases. Important to rule out other causes of persistent symptoms including infectious processes. Rebronch can be helpful for infectious work up and/or determining the nature of the inflammatory process that is ongoing (for example, the ...

When (if ever) do you check for anti-platelet antibodies for workup of thrombocytopenia?

1 Answers

Mednet Member
Mednet Member
Hematology · University of Washington

Routinely available anti-platelet antibody tests have a sensitivity too high and specificity too low to be of much clinical use. A patient's response to first line therapy (steroids or IVIg) is most telling and if there is no response, a bone marrow is warranted as it would be atypical for ITP. Ther...

How would you adjust the steroid dose for steroid-induced psychosis in a patient being treated for secondary HLH with the HLH-94 protocol?

1 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · UCSF Medical Center-Mission Bay

If disease status allows weaning, we slowly wean per recommendations in HLH94. If they need steroids because of significant hyperinflammation that is damaging, then we add risperidone, which generally works very well.

Would you anticoagulate a patient with splenic infarctions in the setting of CMV viremia?

1 Answers

Mednet Member
Mednet Member
Hematology · Medical University of South Carolina

Based on my general knowledge/experience, I would consider CMV viremia as temporary, short-lived risk factor for a thrombotic event on a part of other inflammatory conditions, and outside of other indications for anticoagulation (e.g., atrial fibrillation, etc), my inclination would be to conclude ...

Does the presence of asparaginase antibodies on Granger Genetics testing indicate need to switch asparaginase formulations?

1 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Seattle Children's Hospital, University of Washington

I would rely on the serum asparaginase activity (SAA) assay rather than the antibody testing. SAA has proven to be a reliable predictor of asparagine depletion and is a widely acceptable method for therapeutic drug monitoring. On the other hand, asparaginase antibody testing has not been consistentl...

Would you recommend hematopoietic stem cell transplant for AYAs with Ph-like ALL?

1 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Loma Linda University Health

There are very scarce data about transplant outcomes in patients with Philadelphia chromosome–like B ALL; therefore, the EBMT and ASTCT have no clear indications for HCT in patients with Philadelphia chromosome–like B ALL in CR1. There are multiple factors that can affect the decision on when to pro...

How do you approach evaluation and management of arthralgia in a patient after CAR-T cell therapy?

2
1 Answers

Mednet Member
Mednet Member
Rheumatology · Ohio State University

This is a great question - part of cytokine release at syndrome includes joint pain. So my questions are: How far after? What was the reason for the CAR-T? These are vital questions to understand first. To that be said - the answers will determine if you give a one-and-done treatment or long-term....

What is your approach to working up diarrhea in an immunocompromised patient?

1
1 Answers

Mednet Member
Mednet Member
Rheumatology · Mobile Medical Care Inc

Tough question and very common in clinical and research management. The approach is going to mirror any new complaint and start with a history. Diarrhea means many things to many patients/clinical trial subjects, so characterizing duration, frequency in a day, nocturnal events (diarrhea that occurs ...

How do you approach treatment of sub-total resected ZFTA fusion ependymoma after radiation therapy in a young adult?

1 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · University of Toronto Faculty of Medicine

Thank you for asking.ACNS0831 has shown that there is no benefit of adjuvant chemotherapy in patients with incomplete resection. This was based on a comparison between ACNS0121 where patients did not receive any chemo after XRT and ACNS0831 where all patients with residual received adjuvant chemothe...

How do you approach delivering ISRT to nodular lymphocyte predominant Hodgkin Lymphoma that has responded on FDG-PET/CT after chemotherapy?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University Hospital Basel

The therapeutic algorithm in stage >I lymphocyte predominant HL is extrapolated from data on classic HL. Thus, I would use the same algorithm as in HL when evaluating RT indication and dose. Omitting radiotherapy is safe, if a favorable response has been documented on PET-CT and the patient has rece...